{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:49:45Z","timestamp":1791895785821,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.schres.2026.09.001","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:59:28Z","timestamp":1788965968000},"page":"445-453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Projected mortality impact of increasing second-generation long-acting injectable antipsychotic exposure in Italy: A scenario-based population model"],"prefix":"10.1016","volume":"297","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3344-1000","authenticated-orcid":false,"given":"Vassilis","family":"Martiadis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Raffone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Cervino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Olivola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azzurra","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Pessina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Scognamiglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2026.09.001_bb0005","series-title":"L\u2019uso dei farmaci in Italia. Rapporto OsMed 2024","author":"AIFA","year":"2025"},{"key":"10.1016\/j.schres.2026.09.001_bb0010","unstructured":"AIFA, n.d. Spesa e consumo relativi al flusso della farmaceutica convenzionata e degli acquisti diretti, anni 2016\u20132024. Agenzia Italiana del Farmaco, Rome. Available at: https:\/\/www.aifa.gov.it\/spesa-e-consumo-relativi-al-flusso-della-farmaceutica-convenzionata-e-degli-acquisti-diretti. Accessed 8 May 2026."},{"key":"10.1016\/j.schres.2026.09.001_bb0015","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1192\/bjp.166.6.783","article-title":"Mortality among patients with psychiatric illness: a ten-year case register study in an area with a community-based system of care","volume":"166","author":"Amaddeo","year":"1995","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0020","series-title":"The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia","year":"2021"},{"key":"10.1016\/j.schres.2026.09.001_bb0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41380-024-02694-3","article-title":"All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis","volume":"30","author":"Aymerich","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1192\/apt.bp.114.013565","article-title":"Why are long-acting injectable antipsychotics still underused?","volume":"21","author":"Bosanac","year":"2015","journal-title":"BJPsych Adv."},{"key":"10.1016\/j.schres.2026.09.001_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.15032su1","article-title":"The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence","volume":"77","author":"Correll","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0040","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0045","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-022-04071-2","article-title":"Off-label long acting injectable antipsychotics in real-world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR network DEPOT study","volume":"22","author":"D\u2019Agostino","year":"2022","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0050","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0055","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","article-title":"Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7","volume":"15","author":"Eddy","year":"2012","journal-title":"Value Health."},{"key":"10.1016\/j.schres.2026.09.001_bb0060","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S2215-0366(19)30132-4","article-title":"The Lancet Psychiatry commission: a blueprint for protecting physical health in people with mental illness","volume":"6","author":"Firth","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"9","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0070","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2012.739708","article-title":"World federation of societies of biological psychiatry guidelines for biological treatment of schizophrenia, part 2: long-term treatment","volume":"14","author":"Hasan","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0075","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0080","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.8810","article-title":"Comparison of long-acting injectable antipsychotics with oral antipsychotics and suicide and all-cause mortality in patients with newly diagnosed schizophrenia","volume":"4","author":"Huang","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.schres.2026.09.001_bb0085","series-title":"Cancellati dall\u2019anagrafe per decesso: dati per classi di et\u00e0, decessi e tasso di mortalit\u00e0 per mille abitanti, anno 2024","author":"ISTAT","year":"2026"},{"key":"10.1016\/j.schres.2026.09.001_bb0090","first-page":"66","article-title":"Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies","volume":"8","author":"Kane","year":"2009","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0095","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2020.2076","article-title":"Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial","volume":"77","author":"Kane","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0100","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/schbul\/sbs150","article-title":"Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials","volume":"40","author":"Kishimoto","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2026.09.001_bb0105","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","article-title":"Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies","volume":"8","author":"Kishimoto","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0110","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0115","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/BF01734542","article-title":"Excess mortality by natural causes of Italian schizophrenic patients","volume":"239","author":"Lesage","year":"1990","journal-title":"Eur. Arch. Psychiatry Neurol. Sci."},{"key":"10.1016\/j.schres.2026.09.001_bb0120","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2026.09.001_bb0125","doi-asserted-by":"crossref","DOI":"10.1186\/1471-244X-13-340","article-title":"Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness","volume":"13","author":"Llorca","year":"2013","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eurpsy.2018.04.004","article-title":"Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study","volume":"52","author":"Llorca","year":"2018","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0135","doi-asserted-by":"crossref","DOI":"10.1017\/S2045796022000014","article-title":"The quality of mental health care delivered to patients with schizophrenia and related disorders in the Italian mental health system: the QUADIM project","volume":"31","author":"Lora","year":"2022","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"10.1016\/j.schres.2026.09.001_bb0140","article-title":"Diagnostic pathways and mortality across psychotic disorders: evidence from Catalonia integrated health records","author":"Madero","year":"2025","journal-title":"Span. J. Psychiatry Ment. Health."},{"key":"10.1016\/j.schres.2026.09.001_bb0145","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018359","article-title":"Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis","volume":"8","author":"Marcellusi","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.schres.2026.09.001_bb0150","series-title":"Rapporto Salute Mentale: analisi dei dati del Sistema Informativo per la Salute Mentale, anno 2024","author":"Ministero della Salute","year":"2026"},{"key":"10.1016\/j.schres.2026.09.001_bb0155","series-title":"Psychosis and Schizophrenia in Adults: Prevention and Management. Clinical Guideline CG178","author":"NICE","year":"2014"},{"key":"10.1016\/j.schres.2026.09.001_bb0160","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jamapsychiatry.2015.1737","article-title":"Premature mortality among adults with schizophrenia in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0165","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.schres.2016.11.010","article-title":"Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies","volume":"183","author":"Ostuzzi","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2026.09.001_bb0170","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/wps.20972","article-title":"Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants","volume":"21","author":"Ostuzzi","year":"2022","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12888-020-02530-2","article-title":"Attitudes of European physicians towards the use of long-acting injectable antipsychotics","volume":"20","author":"Patel","year":"2020","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0180","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.2147\/PRBM.S371991","article-title":"Practical guidance for the use of long-acting injectable antipsychotics in the treatment of schizophrenia","volume":"15","author":"Riboldi","year":"2022","journal-title":"Psychol. Res. Behav. Manag."},{"key":"10.1016\/j.schres.2026.09.001_bb0185","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0190","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.psychres.2014.11.002","article-title":"A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders","volume":"225","author":"Sendt","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2026.09.001_bb0195","article-title":"Guidelines for accurate and transparent health estimates reporting: the GATHER statement","volume":"13","author":"Stevens","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.schres.2026.09.001_bb0200","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.schres.2017.12.010","article-title":"Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia","volume":"197","author":"Taipale","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2026.09.001_bb0205","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"issue":"Suppl. 4","key":"10.1016\/j.schres.2026.09.001_bb0210","first-page":"1","article-title":"The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness","volume":"70","author":"Velligan","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0215","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","article-title":"AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users","volume":"34","author":"Vemer","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.schres.2026.09.001_bb0220","doi-asserted-by":"crossref","DOI":"10.1186\/s12991-022-00430-1","article-title":"Achieving long-term goals through early personalized management of schizophrenia: expert opinion on the role of a new fast-onset long-acting injectable antipsychotic","volume":"22","author":"Vita","year":"2023","journal-title":"Ann. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0225","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","article-title":"Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis","volume":"72","author":"Walker","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2026.09.001_bb0230","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S2215-0366(23)00005-6","article-title":"Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST)","volume":"10","author":"Winter-van Rossum","year":"2023","journal-title":"Lancet Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426002884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426002884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:11:34Z","timestamp":1791893494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996426002884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":46,"alternative-id":["S0920996426002884"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2026.09.001","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Projected mortality impact of increasing second-generation long-acting injectable antipsychotic exposure in Italy: A scenario-based population model","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2026.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}